Xenon Pharmaceuticals reported that azetukalner, a Kv7 potassium channel opener, met the primary endpoint in the Phase III X‑TOLE2 study for focal onset seizures and will pursue an NDA filing later this year. The high‑dose cohort produced a large placebo‑adjusted median seizure frequency reduction, outperforming prior Phase II data and prompting a strong market reaction. Xenon framed the data as validating Kv7 as a clinically meaningful target after earlier setbacks with the class. Company management said safety and once‑daily oral dosing support a practical profile for patients with treatment‑resistant focal epilepsy. The readout has immediate regulatory implications as Xenon prepares an FDA submission and aims to capitalize on a sizeable unmet need for novel oral antiseizure mechanisms. Market participants reacted quickly: Xenon’s stock surged on the announcement, and analysts noted the potential to re‑energize interest in Kv7-targeted programs following historic class withdrawals.